NASDAQ:RSLS ReShape Lifesciences (RSLS) Stock Price, News & Analysis $5.74 +0.26 (+4.74%) (As of 10/28/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About ReShape Lifesciences Stock (NASDAQ:RSLS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ReShape Lifesciences alerts:Sign Up Key Stats Today's Range$5.22▼$5.7450-Day Range$4.95▼$10.1252-Week Range$4.60▼$34.22Volume95,027 shsAverage Volume94,874 shsMarket Capitalization$2.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company OverviewReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.Read More… We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. ReShape Lifesciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks32nd Percentile Overall ScoreRSLS MarketRank™: ReShape Lifesciences scored higher than 32% of companies evaluated by MarketBeat, and ranked 841st out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for ReShape Lifesciences.Read more about ReShape Lifesciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioReShape Lifesciences has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about ReShape Lifesciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.13% of the float of ReShape Lifesciences has been sold short.Short Interest Ratio / Days to CoverReShape Lifesciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ReShape Lifesciences has recently decreased by 74.30%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldReShape Lifesciences does not currently pay a dividend.Dividend GrowthReShape Lifesciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.13% of the float of ReShape Lifesciences has been sold short.Short Interest Ratio / Days to CoverReShape Lifesciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ReShape Lifesciences has recently decreased by 74.30%, indicating that investor sentiment is improving significantly. News and Social Media4.1 / 5News Sentiment1.43 News SentimentReShape Lifesciences has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ReShape Lifesciences this week, compared to 1 article on an average week.Search Interest5 people have searched for RSLS on MarketBeat in the last 30 days. MarketBeat Follows1 people have added ReShape Lifesciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ReShape Lifesciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of ReShape Lifesciences is held by insiders.Percentage Held by InstitutionsOnly 22.06% of the stock of ReShape Lifesciences is held by institutions.Read more about ReShape Lifesciences' insider trading history. Receive RSLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ReShape Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RSLS Stock News HeadlinesReshape Lifesciences (NASDAQ:RSLS) Stock, Short Interest ReportSeptember 24, 2024 | benzinga.comReshape Lifesciences (NASDAQ:RSLS) Stock Quotes, Forecast and News SummarySeptember 24, 2024 | benzinga.comWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…October 29, 2024 | Porter & Company (Ad)Upcoming Stock Splits This Week (September 23 to September 27) – Stay InvestedSeptember 23, 2024 | msn.comReShape Lifesciences Announces 1-for-58 Reverse Stock SplitSeptember 19, 2024 | globenewswire.comNexstim Oyj (5NX.MU)August 22, 2024 | finance.yahoo.comQ2 2024 ReShape Lifesciences Inc Earnings CallAugust 16, 2024 | finance.yahoo.comReShape Lifesciences Inc. (NASDAQ:RSLS) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | msn.comSee More Headlines RSLS Stock Analysis - Frequently Asked Questions How have RSLS shares performed this year? ReShape Lifesciences' stock was trading at $14.4826 at the start of the year. Since then, RSLS stock has decreased by 60.4% and is now trading at $5.74. View the best growth stocks for 2024 here. How were ReShape Lifesciences' earnings last quarter? ReShape Lifesciences Inc. (NASDAQ:RSLS) released its quarterly earnings results on Wednesday, August, 14th. The medical device company reported ($3.48) earnings per share (EPS) for the quarter. The medical device company earned $1.97 million during the quarter. ReShape Lifesciences had a negative net margin of 112.11% and a negative trailing twelve-month return on equity of 208.37%. When did ReShape Lifesciences' stock split? Shares of ReShape Lifesciences reverse split before market open on Monday, September 23rd 2024. The 1-58 reverse split was announced on Thursday, September 19th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of ReShape Lifesciences? Shares of RSLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ReShape Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that ReShape Lifesciences investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Block (SQ), Digital Turbine (APPS), Nano Dimension (NNDM), CrowdStrike (CRWD) and Palantir Technologies (PLTR). Company Calendar Last Earnings8/14/2024Today10/29/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:RSLS CUSIP29365M20 CIK1371217 Webwww.reshapelifesciences.com Phone(949) 429-6680FaxN/AEmployees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,390,000.00 Net Margins-112.11% Pretax Margin-111.32% Return on Equity-208.37% Return on Assets-108.96% Debt Debt-to-Equity RatioN/A Current Ratio1.90 Quick Ratio0.89 Sales & Book Value Annual Sales$8.68 million Price / Sales0.34 Cash FlowN/A Price / Cash FlowN/A Book Value$29.49 per share Price / Book0.19Miscellaneous Outstanding Shares510,000Free Float504,000Market Cap$2.93 million OptionableNot Optionable Beta1.42 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:RSLS) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ReShape Lifesciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ReShape Lifesciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.